Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
News
-
November 10, 2022Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement
-
November 3, 2022Targovax ASA: Third quarter 2022 results
-
October 26, 2022Invitation to Targovax’s third quarter 2022 presentation, Thursday 3 November
-
October 20, 2022The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info
Q3 interim report 2022
Targovax ASA (OSE: TRVX) announced its third quarter 2022 results on Thursday 3 November 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press.